LAZR Investors Have Opportunity to Join Luminar Technologies, Inc. Fraud Investigation with the Schall Law Firm
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Luminar announced in a May 14, 2025, press release "the resignation of founder Austin Russell as President and CEO of the company and as the Chairperson of the Board, effective immediately, following a Code of Business Conduct and Ethics inquiry by the Audit Committee of the Board of Directors." Based on this news, shares of Luminar fell by more than 16.8% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Analyst downgrades top S&P 500 stock after disappointing earnings
Analyst downgrades top S&P 500 stock after disappointing earnings originally appeared on TheStreet. Compass Point has lowered Coinbase's (Nasdaq: COIN) price target from $330 to $248 and downgraded the rating from "Neutral" to "Sell" after the crypto exchange reported disappointing financial results for the second quarter of 2025. The investment firm indicated receding retail interest, poor Q2 records, weak prospects for recurring revenue lines like subscriptions and custody services the next quarter, and more competition from stablecoin and decentralized finance (DeFi) platforms as the reasons it downgraded the COIN stock's rating. Compass Point also warned of Coinbase's retail trading under pressure despite a bullish crypto market. Notably, retail trading is Coinbase's main profit are two other factors that the firm highlighted as possible risks for Coinbase. One is a potential delay in the CLARITY Act, which deals with classifying the financial status of crypto assets. Another is Coinbase trailing Robinhood (Nasdaq: HOOD) and Kraken in launching stock trading. 'We see limited support for COIN's valuation if crypto markets sell off further,' said Compass Point. Founded in 2012, Coinbase is the largest crypto exchange in the U.S. The company, which went public in April 2021, joined the S&P 500 list in May 2025 — the only crypto stock to be included in the hotly contested list so far. During Q2 2025, the exchange generated $1.5 billion in total revenue, $1.4 billion in net income, and earnings per share (EPS) of $5.14 in Q2. The exchange held 11,776 Bitcoin worth $1.3 billion by the end of the quarter. The COIN stock is trading at $319.55 at the time of writing, up 1.54% a day. Analyst downgrades top S&P 500 stock after disappointing earnings first appeared on TheStreet on Aug 4, 2025 This story was originally reported by TheStreet on Aug 4, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Why Applied Digital Stock Skyrocketed This Week
Key Points Applied Digital posted big gains in conjunction with the quarterly results it published this week. The company's results in fiscal Q4 beat Wall Street's targets. Applied Digital announced that CoreWeave exercised an option to significantly expand its data center contract. 10 stocks we like better than Applied Digital › Despite a pullback on Friday driven by bearish macroeconomic news, Applied Digital (NASDAQ: APLD) stock managed to close out this week's trading with big gains. The company's share price ended the stretch up 16.5% compared to where it stood at the end of the previous week's market close. Applied Digital's big rally this week stemmed from posting its report for the fourth quarter of its last fiscal year, which ended May 31. In addition to posting better-than-expected results for fiscal Q4, the company announced a major new contract with CoreWeave that helped send shares soaring. Applied Digital beat Wall Street's targets for fiscal Q4 Applied Digital published results for fiscal Q4 after the market closed on July 30, and the report and investor conference powered a massive rally for the company's share price. The data center specialist reported a non-GAAP (adjusted) loss of $0.03 per share for the period, which came in far better than the average analyst estimate's call for a per-share loss of $0.16. Meanwhile, sales for the period came in at $38 million, which beat the average analyst estimate by roughly $880,000. Sales were up 41% year over year in the period, and the company paired the encouraging quarterly results with huge news about its relationship with CoreWeave. CoreWeave's contract move flashes green flag for Applied Digital stock In conjunction with its fiscal Q4 report, Applied Digital announced that CoreWeave had moved to exercise an option to secure an additional 150 megawatts of data center processing usage. Applied Digital revealed that it had entered into a $7 billion, 250-megawatt data center contract with the artificial intelligence (AI) specialist at the beginning of July, and news that its partner had quickly decided to sign on for the extra processing megawatts prompted explosive gains for the stock. Should you buy stock in Applied Digital right now? Before you buy stock in Applied Digital, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Applied Digital wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Applied Digital Stock Skyrocketed This Week was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
14 minutes ago
- Business Upturn
Biofrontera Inc. to Report Second Quarter FY 2025 Financial Results on August 13, 2025
Woburn, MA, Aug. 04, 2025 (GLOBE NEWSWIRE) — Biofrontera Inc., (Nasdaq:BFRI) ('Biofrontera' or the 'Company'), a biopharmaceutical company specializing in the commercialization of dermatological products, announces it will report financial results for the three and six months ended June 30, 2025 on Wednesday, August 13, 2025. The results will be released after the market close on Wednesday, August 13 and the company will host a conference call on Thursday, August 14 at 10:00am Eastern Time. Conference Call and Webcast Information Advertisement About Biofrontera Inc. Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit and follow Biofrontera on LinkedIn and X. Contacts: Investor Relations Andrew Barwicki 1-516-662-9461 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
